Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309945 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 889
- Enrollment target
NCT01309945: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01309945 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 889 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (568% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01309945, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 889 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
Interventions
- DRUG Duloxetine
- DRUG BMS-820836
- DRUG Placebo matching with BMS-820836
- DRUG Placebo matching with Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 889 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT01309945 record still lists
NCT01309945 is an interventional study that assigns participants to a tested intervention. The registered 889 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (568% higher).
The record links to 0 conditions, and to 4 interventions - of which Duloxetine is the first listed.
NCT01309945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01309945 about?
NCT01309945 is a clinical study titled "Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression". The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
What is the current status of trial NCT01309945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 889 participants. The study started on 2011-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01309945?
The interventions under investigation include: Duloxetine (DRUG), BMS-820836 (DRUG), Placebo matching with BMS-820836 (DRUG), Placebo matching with Duloxetine (DRUG).
Who is sponsoring clinical trial NCT01309945?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01309945's enrollment target sits among peer trials
889 33rd of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia